 Nathan Gomes
Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| High-Throughput Screening Assays | 1 | 2023 | 123 | 0.760 |
Why?
| | Gene Expression Regulation | 3 | 2010 | 2320 | 0.550 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2010 | 445 | 0.540 |
Why?
| | Positive Transcriptional Elongation Factor B | 3 | 2006 | 22 | 0.530 |
Why?
| | RNA Polymerase II | 4 | 2010 | 284 | 0.470 |
Why?
| | Chromosomal Proteins, Non-Histone | 2 | 2010 | 100 | 0.420 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2010 | 171 | 0.410 |
Why?
| | Promoter Regions, Genetic | 3 | 2010 | 1131 | 0.360 |
Why?
| | Repressor Proteins | 2 | 2010 | 366 | 0.350 |
Why?
| | Chromatin | 2 | 2010 | 428 | 0.340 |
Why?
| | Proto-Oncogene Proteins | 2 | 2010 | 608 | 0.340 |
Why?
| | Genes, p53 | 1 | 2010 | 61 | 0.340 |
Why?
| | Cell Cycle Proteins | 2 | 2010 | 551 | 0.330 |
Why?
| | Neoplasms | 1 | 2023 | 2097 | 0.330 |
Why?
| | Gene Products, tat | 2 | 2005 | 19 | 0.270 |
Why?
| | Peptides, Cyclic | 2 | 2020 | 253 | 0.260 |
Why?
| | HIV Long Terminal Repeat | 1 | 2003 | 8 | 0.210 |
Why?
| | Transcription, Genetic | 2 | 2006 | 1313 | 0.210 |
Why?
| | Biochemistry | 1 | 2003 | 40 | 0.200 |
Why?
| | Drug Discovery | 1 | 2023 | 123 | 0.200 |
Why?
| | Protein Structure, Tertiary | 4 | 2010 | 796 | 0.190 |
Why?
| | HIV-1 | 2 | 2005 | 768 | 0.180 |
Why?
| | CCCTC-Binding Factor | 2 | 2010 | 12 | 0.180 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 42 | 0.170 |
Why?
| | HCT116 Cells | 2 | 2010 | 70 | 0.150 |
Why?
| | Chromatin Immunoprecipitation | 2 | 2010 | 128 | 0.150 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 107 | 0.150 |
Why?
| | Cell Line | 1 | 2023 | 2637 | 0.140 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 329 | 0.130 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2765 | 0.130 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2015 | 38 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 427 | 0.130 |
Why?
| | Kinetics | 2 | 2010 | 1551 | 0.120 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 2710 | 0.100 |
Why?
| | Nuclear Proteins | 2 | 2006 | 591 | 0.090 |
Why?
| | Transcription Factors, General | 1 | 2010 | 5 | 0.090 |
Why?
| | HeLa Cells | 3 | 2015 | 562 | 0.090 |
Why?
| | Peptide Elongation Factors | 1 | 2010 | 13 | 0.090 |
Why?
| | fas Receptor | 1 | 2010 | 91 | 0.090 |
Why?
| | CCAAT-Binding Factor | 1 | 2010 | 4 | 0.090 |
Why?
| | Apoptosis | 2 | 2010 | 2363 | 0.080 |
Why?
| | RNA, Untranslated | 1 | 2010 | 113 | 0.080 |
Why?
| | Humans | 9 | 2023 | 114699 | 0.080 |
Why?
| | Transcription Factors | 2 | 2006 | 1528 | 0.070 |
Why?
| | Protein Binding | 2 | 2010 | 1890 | 0.070 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 2005 | 20 | 0.070 |
Why?
| | Transcription Factors, TFII | 1 | 2006 | 37 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2010 | 430 | 0.060 |
Why?
| | Transcription Factor TFIIH | 1 | 2006 | 34 | 0.060 |
Why?
| | Transcriptional Elongation Factors | 1 | 2006 | 32 | 0.060 |
Why?
| | High Mobility Group Proteins | 1 | 2006 | 49 | 0.060 |
Why?
| | Histones | 1 | 2010 | 535 | 0.060 |
Why?
| | Serine | 1 | 2006 | 126 | 0.060 |
Why?
| | Protein Isoforms | 1 | 2006 | 338 | 0.060 |
Why?
| | Doxorubicin | 1 | 2006 | 285 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 923 | 0.060 |
Why?
| | Cyclin T | 1 | 2003 | 2 | 0.050 |
Why?
| | Chromatography | 1 | 2003 | 23 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2003 | 93 | 0.050 |
Why?
| | Cyclins | 1 | 2003 | 78 | 0.050 |
Why?
| | Flow Cytometry | 1 | 2006 | 1083 | 0.050 |
Why?
| | Phosphorylation | 1 | 2006 | 1569 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2003 | 337 | 0.050 |
Why?
| | Blotting, Western | 1 | 2003 | 1147 | 0.040 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2003 | 554 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 127 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1230 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 244 | 0.040 |
Why?
| | DNA | 1 | 2006 | 1352 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2006 | 1314 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 188 | 0.040 |
Why?
| | DNA Repair | 1 | 2020 | 184 | 0.040 |
Why?
| | DNA Damage | 1 | 2020 | 351 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 698 | 0.040 |
Why?
| | Cell Cycle | 1 | 2020 | 542 | 0.030 |
Why?
| | RNA | 1 | 2003 | 809 | 0.030 |
Why?
| | Models, Biological | 1 | 2003 | 1621 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 858 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2015 | 386 | 0.030 |
Why?
| | Glioma | 1 | 2015 | 294 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2015 | 979 | 0.020 |
Why?
| | Nuclear Receptor Coactivators | 1 | 2005 | 3 | 0.020 |
Why?
| | Ribonucleoprotein, U5 Small Nuclear | 1 | 2005 | 11 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2005 | 117 | 0.010 |
Why?
| | Multiprotein Complexes | 1 | 2005 | 140 | 0.010 |
Why?
| | Mice | 1 | 2020 | 14871 | 0.010 |
Why?
| | Alternative Splicing | 1 | 2005 | 187 | 0.010 |
Why?
| | Animals | 1 | 2020 | 31708 | 0.010 |
Why?
| | Female | 1 | 2020 | 59520 | 0.010 |
Why?
|
|
Gomes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|